Board certified in general surgery, Dr. Levine’s clinical interests are focused on treating patients with mesothelioma, sarcoma, melanoma, breast cancer, esophageal tumors/cancer, peritoneal carcinomatosis, and gastrointestinal cancers.
A world-renowned expert in treating peritoneal malignancies with hyperthermic intraperitoneal chemotherapy (HIPEC), Dr. Levine has stated that “Long-term survival is clearly possible for selected patients treated with HIPEC.” An analysis of two decades of data examining 1,000 patients who underwent 1,095 HIPEC procedures at Wake Forest Baptist – 7.2% where mesothelioma was a primary tumor site – demonstrated a median overall survival of 29.9 months, with a five-year survival of 32.5%.
Levine continues to research chemotherapy, cancer, regional perfusion, peritoneal neoplasms, and antineoplastic combined chemotherapy, while investigating treatment options through active clinical trials.
Main Speciality: General Surgery
Other Interests & Specialties: General surgery, breast cancer, melanoma, mesothelioma, peritoneal mesothelioma, abdominal cancer, peritoneal carcinomatosis, hyperthermic intraperitoneal chemotherapy (HIPEC), colorectal cancer, sentinel lymph node mapping, cytoreductive surgery and surgical oncology (other than breast).
Certifications, Awards & Accolades: American Board of Surgery Certification, CMS Stage 1 EHR Certification, ACS Fellow, America’s Top Doctors Award, America’s Top Doctors for Cancer Award, member of the Society of Surgery of the Alimentary Tract, North Carolina Medical Society, Southern Association for Oncology, Southern Medical Association, Southern Surgical Association, Southern Surgical Congress, American College of Surgeons, Association of Academic Surgery, Connective Tissue Oncology Society, Alpha Omega Alpha, Winston-Salem Surgical Society, and The Americas Hepato-Pancreato Biliary Association
Education & Experience:
- Residency for General Surgery at Michael Reese Hospital and Medical Center
- Fellowship for Surgical Oncology at Abe Lincoln School of Medicine – University of Illinois
- Medical Degree from Chicago Medical School at Rosalind Franklin University
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Annals of surgical oncology. October 2010;17(10):2720-7. doi: 10.1245/s10434-010-1080-6
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. Journal of Clinical Oncology. December 2009;27(36):6237-42. doi: 10.1200/JCO.2009.23.9640
Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. American Journal of Clinical Pathology. September 2007;128(3):414-22. doi: 10.1309/DV1JYBL8LLYYT4J5
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Modern Pathology. April 2004;17(4):476-81. doi: 10.1038/modpathol.3800067
Changing pattern in malignant mesothelioma survival. Translational Oncology. February 2015;8(1):35-39. doi: 10.1016/j.tranon.2014.12.002
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs